{"id":"01820","slug":"anti-hla-a2-b17-mab-ho-2-and--01820","source":{"id":"01820","dataset":"techtransfer","title":"Anti-HLA-A2,B17 MAb HO-2 and Hybridoma Cell Line","description_":"<p><h2>Description</h2>Major histocompatibility complex (MHC) is a cell surface molecule that mediates interactions with immune cells thru the presentation of peptides. MHC is dived into three groups; class I, class II, and class III. The human leukocyte antigen (HLA) is the corresponding name of the major histocompatibility complex (MHC) in humans. HLA molecules are divided into two subgroups; class I and II. HLA class I molecules (A, B, and C) present intracellular peptides to immune cells. Monoclonal antibody HO-2 recognizes HLA-A2 and HLA-B17.</p><p></p><p></p><p></p><p><h2>IP Status</h2>Research Tool</p><p></p>","tags":[],"file_number":"01820","collections":[],"meta_description":"HO-2 monoclonal antibody targets human HLA-A2 and B17; useful as a research tool for MHC class I studies.","image_url":"","apriori_judge_output":"{\"scores\":{\"novelty\":2.0,\"potential_impact\":2.0,\"readiness\":2.0,\"scalability\":2.0,\"timeliness\":1.0},\"weighted_score\":1.75,\"risks\":[\"Outdated (2008) with >3 years since reference\",\"Limited current market relevance due to niche HLA subtypes\",\"Hybridoma-based tool may have competition from recombinant antibodies\",\"Potential IP and licensing constraints\",\"Lack of clear clinical validation data\"],\"one_sentence_take\":\"Moderate novelty and potential impact for a legacy research tool, but timeliness and readiness are weak due to age and limited clinical validation.\"}","lead_inventor_name":"Soldano Ferrone","lead_inventor_dept":"Department of Surgery","technology_type":"Life Science Research Tool","technology_subtype":"Cell Line","therapeutic_areas":[],"therapeutic_indications":[],"custom_tags":[],"all_tech_innovators":["Soldano Ferrone"],"date_submitted":"2008-09-03"},"highlight":{},"matched_queries":null,"score":0.0}